21
Participants
Start Date
February 15, 2010
Primary Completion Date
November 11, 2010
Study Completion Date
November 11, 2010
Tanezumab
IV, 5 mg dose, q 8 weeks, for up to 80 weeks
Tanezumab
IV, 10 mg dose, q 8 weeks, for up to 80 weeks
Placebo
IV, q 8 weeks, for up to 80 weeks
Blair Neurologic Associates, Altoona
Altoona Center for Clinical Research, Duncansville
Asheville Imaging, Asheville
Biltmore Medical Associates, Asheville
Clinical Study Center of Asheville, LLC, Asheville
Coastal Carolina Research Center in Goose Creek, Goose Creek
Tidewater Neurology, Goose Creek
Arthritis & Rheumatic Care Center, South Miami
Miami Research Associates, South Miami
Neuroscience Consultants, LLC, South Miami
Jem Research, LLC, Atlantis
Medical Specialists of the Palm Beaches, Atlantis
Clinical Physiology Associates, Clinical Study Center, Fort Myers
Harris Bonnette, MD, Fort Myers
Ohio Research Center, Toledo
Neurodiagnostic Laboratories of San Antonio, Inc, San Antonio
Radiant Research, Inc., San Antonio
Asheville Neurology, Asheville
Lead Sponsor
Pfizer
INDUSTRY